G. ÜNAL Et Al. , "Famotidine Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK 3," 29th European College of Neuropsychopharmacology (ECNP) Congress , vol.26, Viyana, Austria, 2016
ÜNAL, G. Et Al. 2016. Famotidine Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK 3. 29th European College of Neuropsychopharmacology (ECNP) Congress , (Viyana, Austria).
ÜNAL, G., Dokumacı, A. H., HAZAR YAVUZ, A. N., AYCAN, M. B., Şahin, C., KELEŞ, R. M., ... ARICIOĞLU, F.(2016). Famotidine Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK 3 . 29th European College of Neuropsychopharmacology (ECNP) Congress, Viyana, Austria
ÜNAL, GÖKHAN Et Al. "Famotidine Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK 3," 29th European College of Neuropsychopharmacology (ECNP) Congress, Viyana, Austria, 2016
ÜNAL, GÖKHAN Et Al. "Famotidine Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK 3." 29th European College of Neuropsychopharmacology (ECNP) Congress , Viyana, Austria, 2016
ÜNAL, G. Et Al. (2016) . "Famotidine Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK 3." 29th European College of Neuropsychopharmacology (ECNP) Congress , Viyana, Austria.
@conferencepaper{conferencepaper, author={GÖKHAN ÜNAL Et Al. }, title={Famotidine Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK 3}, congress name={29th European College of Neuropsychopharmacology (ECNP) Congress}, city={Viyana}, country={Austria}, year={2016}}